David N Radin

US Patent:

8431774, Apr 30, 2013

Filed:

Oct 6, 2009

Appl. No.:

12/574598

Inventors:

Carole L. Cramer - Jonesboro AR, US
Maureen C. Dolan - Jonesboro AR, US
Giuliana Medrano - Jonesboro AR, US
David N. Radin - Jonesboro AR, US

Assignee:

University of Arkansas-Jonesboro - State University AR

International Classification:

A01H 5/00
C07K 14/54
C12N 15/24
C12N 5/04

US Classification:

800288, 530351, 800295, 800298, 800278, 536 231, 536 235

Abstract:

The invention is a plant-based production of biologically active avian interleukin-12 protein and functional units for increasing the protective and/or immunological response in an animal, for use as an adjuvant with a vaccine to control avian infectious diseases, and methods of producing and using the same. Specifically, avian interleukin-12 was produced from a plant-based expression system and demonstrated that it stimulates production of immune responses in birds.

US Patent:

20130323221, Dec 5, 2013

Filed:

May 30, 2013

Appl. No.:

13/906203

Inventors:

DAVID N. RADIN - JONESBORO AR, US

Assignee:

Biostrategies LC - State University AR

International Classification:

A61K 47/48

US Classification:

424 943

Abstract:

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

US Patent:

20220251522, Aug 11, 2022

Filed:

Feb 15, 2022

Appl. No.:

17/651106

Inventors:

- STATE UNIVERSITY AR, US
DAVID N. RADIN - JONESBORO AR, US

International Classification:

C12N 9/02
C07K 14/42
C12N 9/16
C12N 15/82
A61K 38/17
A61K 38/16
A61K 38/44

Abstract:

The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention.

US Patent:

20170267987, Sep 21, 2017

Filed:

May 26, 2017

Appl. No.:

15/606830

Inventors:

- State University AR, US
DAVID N. RADIN - JONESBORO AR, US

International Classification:

C12N 9/24
C07K 14/54
C07K 16/16
C12N 9/14
A61K 38/00

Abstract:

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

US Patent:

20170191041, Jul 6, 2017

Filed:

Jul 10, 2015

Appl. No.:

15/325661

Inventors:

- STATE UNIVERSITY AR, US
DAVID N. RADIN - JONESBORO AR, US

International Classification:

C12N 9/02
C12N 9/16
A61K 38/16
C07K 14/42
A61K 38/44

Abstract:

The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention.

US Patent:

20160083707, Mar 24, 2016

Filed:

Dec 1, 2015

Appl. No.:

14/956001

Inventors:

- State University AR, US
DAVID N. RADIN - JONESBORO AR, US

International Classification:

C12N 9/24
C12N 9/14
C07K 14/54

Abstract:

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.